| Literature DB >> 34012569 |
Wenyu Zhai1, Yuzhen Zheng2, Yuming Rong3, Xiaoqiang Li4, Qihang Yan1, Fangfang Duan3, Zerui Zhao1, Jianlong Chen5, Shuqin Dai6, Junye Wang1.
Abstract
BACKGROUND: The examination of lymph nodes (LNs) is critical for accurate node staging in patients with non-small cell lung cancer (NSCLC), but a consensus on the examinations of hilar and intrapulmonary (N1 station) LNs has not been reached. This study aimed to evaluate the role of LN dissection and pathological examination of N1 LN stations and their effects on survival in patients with stage IA-IIA NSCLC.Entities:
Keywords: N1; Non-small cell lung cancer (NSCLC); lymph node (LN); prognosis; propensity-score matching
Year: 2021 PMID: 34012569 PMCID: PMC8107558 DOI: 10.21037/jtd-20-3611
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1Kaplan-Meier survival curves for patients with different number of N1 stations examined before PSM. (A) OS for patients with 0–5 N1 stations examined; (B) DFS for patients with 0-5 N1 stations examined; (C) OS for patients with 0–1 and 2–5 N1 stations examined; (D) DFS for patients with 0–1 and 2–5 N1 stations examined before. PSM, propensity score matching; OS, overall survival; DFS, disease-free survival.
Patients characteristics
| Characteristics | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| 0–1 N1 station examined, n=233 | 2–6 N1 stations examined, n=1702 | P value | 0–1 N1 station examined, n=232 | 2–6 N1 stations examined, n=232 | P value | ||
| Gender | 0.483 | 0.849 | |||||
| Male | 144 (61.8) | 1,011 (59.4) | 144 (62.1) | 142 (61.2) | |||
| Female | 89 (38.2) | 691 (40.6) | 88 (37.9) | 90 (37.8) | |||
| Age (year) | 61.3±9.2 | 59.7±9.5 | 0.018* | 61.4±9.0 | 60.9±9.6 | 0.529 | |
| Tumor size (cm) | 2.5±1.0 | 2.5±1.0 | 0.635 | 2.5±1.0 | 2.5±0.9 | 0.744 | |
| 8th TNM stage | 0.882 | 0.926 | |||||
| IA | 106 (45.5) | 816 (47.9) | 105 (45.3) | 104 (44.8) | |||
| IB-IIA | 127 (54.5) | 886 (52.1) | 127 (54.7) | 128 (55.2) | |||
| Histology | 0.770 | 0.490 | |||||
| Adenocarcinoma | 179 (76.8) | 1,314 (77.2) | 179 (34.1) | 189 (81.4) | |||
| Squamous cell carcinoma | 34 (14.6) | 263 (15.4) | 34 (14.7) | 29 (12.5) | |||
| Others | 20 (8.6) | 125 (7.4) | 19 (8.2) | 14 (6.1) | |||
| Differentiation degree | 0.260 | 0.486 | |||||
| Well | 32 (14.8) | 146 (8.7) | 32 (14.8) | 20 (8.6) | |||
| Moderate | 118 (50.8) | 939 (55.2) | 118 (50.8) | 130 (56.0) | |||
| Poor | 82 (35.4) | 614 (36.1) | 82 (35.4) | 82 (35.4) | |||
| Visceral pleura invasion | 0.180 | 0.441 | |||||
| Negative | 152 (65.2) | 1,184 (69.6) | 151 (65.0) | 143 (61.6) | |||
| Positive | 81 (34.8) | 518 (30.4) | 81 (35.0) | 89 (38.4) | |||
| Lymphovascular invasion | 0.096 | 0.441 | |||||
| Negative | 219 (94.0) | 1,587 (93.2) | 218 (94.0) | 216 (93.1) | |||
| Positive | 14 (6) | 115 (6.8) | 14 (6) | 6 (6.9) | |||
| Number of N2 stations examined | 3.1±1.3 | 3.3±1.3 | 0.024* | 3.1±1.3 | 3.2±1.3 | 0.416 | |
| Number of N2 LNs examined | 11.7±7.7 | 13.5±9.0 | 0.004* | 11.7±7.7 | 12.1±8.0 | 0.531 | |
| Surgical approach | 0.993 | 0.508 | |||||
| Lobectomy | 211 (90.6) | 1,541 (90.5) | 210 (90.5) | 214 (92.2) | |||
| others | 22 (9.4) | 161 (9.5) | 22 (9.5) | 18 (7.8) | |||
| Thoracotomy or VATS | 0.401 | 0.853 | |||||
| Thoracotomy | 112 (48.0) | 768 (45.1) | 112 (48.2) | 110 (47.4) | |||
| VATS | 121 (52.0) | 933 (54.9) | 120 (51.8) | 122 (52.6) | |||
*, P<0.05. PSM, propensity score matching; VATS, video-assisted thoracoscopic surgery.
Figure 2Kaplan-Meier survival curves for patients with different number of N1 stations examined after PSM. (A) OS for patients with 0–5 N1 stations examined; (B) OS for patients with 0–1 and 2–5 N1 stations examined; (C) DFS for patients with 0–5 N1 stations examined; (D) DFS for patients with 0–1 and 2–5 N1 stations examined. PSM, propensity score matching; OS, overall survival; DFS, disease-free survival.
Univariate and multivariate analysis of DFS for patients after PSM
| Factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Gender | 0.445 (0.286–0.693) | <0.001* | 0.538 (0.362–0.938) | 0.026* | |
| Age (year) | 1.027 (1.007–1.048) | 0.009* | 1.026 (1.004–1.048) | 0.018* | |
| Tumor size (cm) | 1.548 (1.297–1.847) | <0.001* | 1.033 (0.789–1.354) | 0.811 | |
| 8th TNM stage | 2.825 (1.845–4.326) | <0.001* | 1.604 (1.100–2.339) | 0.014* | |
| Visceral pleura invasion | 1.655 (1.148–2.386) | 0.007* | 1.140 (0.701–1.853) | 0.597 | |
| Histology | |||||
| Squamous cell carcinoma | Ref | ||||
| Adenocarcinoma | 0.633 (0.401–1.000) | 0.050 | |||
| Others | 1.088 (0.544–2.178) | 0.811 | |||
| Differentiation degree | |||||
| Well | Ref | Ref | |||
| Moderate | 1.720 (0.780–3.791) | 0.179 | 1.482 (0.666–3.300) | 0.335 | |
| Poor | 3.166 (1.443–6.947) | 0.004* | 2.144 (0.949–4.841) | 0.067 | |
| Lymphovascular invasion | 2.708 (1.510–4.856) | 0.001* | 1.906 (1.018–3.569) | 0.044* | |
| Number of N2 LNs examined | 1.010 (0.987–1.034) | 0.405 | |||
| Number of N2 stations examined | 0.982 (0.853–1.131) | 0.804 | |||
| Surgical approach | 1.348 (0.757–2.402) | 0.331 | |||
| Thoracotomy or VATS | 0.685 (0.469–0.999) | 0.049* | 0.838 (0.556–1.262) | 0.398 | |
| Number of N1 stations examined | |||||
| 0 N1 station examined | Ref | Ref | |||
| 1 N1 station examined | 0.620 (0.356–1.079) | 0.091 | 0.671 (0.377–1.191) | 0.173 | |
| 2 N1 stations examined | 0.401 (0.200–0.802) | 0.010* | 0.476 (0.232–0.977) | 0.043* | |
| 3 N1 stations examined | 0.347 (0.169–0.711) | 0.004* | 0.269 (0.128–0.562) | <0.001* | |
| 4 N1 stations examined | 0.518 (0.229–1.174) | 0.115 | 0.642 (0.279–1.477) | 0.297 | |
| 5 N1 stations examined | 0.726 (0.165–3.188) | 0.672 | 0.700 (0.158–2.262) | 0.639 | |
*, P<0.05. DFS, disease-free survival; PSM, propensity score matching; VATS, video-assisted thoracoscopic surgery.
Figure 3Kaplan-Meier survival curves for patients with a single N1 station examined after PSM. (A) OS for patients with and without group 12 examined; (B) DFS for patients with and without group 12 examined; (C) OS for patients with and without group 13 or 14 examined; (D) DFS for patients with and without group 13 or 14 examined. PSM, propensity score matching; OS, overall survival; DFS, disease-free survival.